דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים: Cara Therapeutics Inc (CARA)

Cara Therapeutics, Inc. (CARA) demonstrates stability, as its anti-pruritus developments remain independent of GDP and seasonality. The business foundation rests on safe innovations in neuromedicine and loyal demand from nephrology centers. This chart of the rolling 12-month YoY revenue growth confirms the company's resilience to market shocks, while -99.70 determines the latest valuation metric for this revenue trend.
caratherapeutics.com - פילוחים אנליטיים ומדדי מפתח (CARA)

This indicator calculates the percentage deviation of current revenue from the figures of the same period last year, providing a real-time assessment of cash flow dynamics. A stable trend in year-over-year revenue changes using the TTM method confirms the effectiveness of the asset-light model of Cara Therapeutics, Inc. (CARA), where growth in royalties from neuro-drug licensing directly increases profit without capital expenditures, determining the fundamental stability of the share price.